These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34670052)

  • 1. Ruxolitinib for Chronic Graft-versus-Host Disease.
    Shibusawa M
    N Engl J Med; 2021 Oct; 385(17):1631. PubMed ID: 34670052
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib for Chronic Graft-versus-Host Disease.
    Gratwohl A
    N Engl J Med; 2021 Oct; 385(17):1631. PubMed ID: 34670051
    [No Abstract]   [Full Text] [Related]  

  • 3. Ruxolitinib for Chronic Graft-versus-Host Disease. Reply.
    Zeiser R; Teshima T; Locatelli F
    N Engl J Med; 2021 Oct; 385(17):1631-1632. PubMed ID: 34670053
    [No Abstract]   [Full Text] [Related]  

  • 4. New Indication for Ruxolitinib.
    Aschenbrenner DS
    Am J Nurs; 2022 Jan; 122(1):20. PubMed ID: 34941588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management?
    Sisinni L
    Lancet Haematol; 2024 Aug; 11(8):e553-e555. PubMed ID: 39002550
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.
    Lee CJ; Pusic I; Savani BN
    Br J Haematol; 2021 Nov; 195(3):306-307. PubMed ID: 34402041
    [No Abstract]   [Full Text] [Related]  

  • 7. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.
    Pusic I; Lee C; Veeraputhiran M; Minor C; DiPersio JF
    Bone Marrow Transplant; 2024 Feb; 59(2):282-284. PubMed ID: 38071272
    [No Abstract]   [Full Text] [Related]  

  • 9. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
    Abedin SM; Hamadani M
    Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
    Saraceni F; Scortechini I; Mancini G; Mariani M; Federici I; Gaetani M; Barbatelli P; Minnucci ML; Bagnarelli P; Olivieri A
    Transpl Infect Dis; 2021 Feb; 23(1):e13401. PubMed ID: 32629531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience.
    Wang YL; Chang TY; Wen YC; Yang SH; Hsiao YW; Chen SH; Jaing TH
    Pediatr Neonatol; 2024 Jan; 65(1):85-86. PubMed ID: 37951828
    [No Abstract]   [Full Text] [Related]  

  • 13. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
    Foss FM; Rubinowitz A; Landry ML; Isufi I; Gowda L; Seropian S; Perreault S; Shenoi SV
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):720-723. PubMed ID: 32727701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD.
    Hudda Z; Flannery A; Teusink-Cross A; Davies SM; Khandelwal P
    Bone Marrow Transplant; 2024 Mar; 59(3):425-427. PubMed ID: 38182673
    [No Abstract]   [Full Text] [Related]  

  • 15. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
    Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
    Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
    Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
    Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Clinical Observation with Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Children with Thalassemia after Unrelated or Haploidentical Allo-Hematopoietic Stem Cell Transplantation].
    Chen YM; Hong XL; Lin JZ; Shi J; Lu QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1586-1589. PubMed ID: 36208270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
    Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
    Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.
    Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y
    Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host disease.
    Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
    J Oncol Pharm Pract; 2022 Jun; 28(4):983-985. PubMed ID: 35019785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.